Madrigal's 15-minute chart shows MACD Death Cross and KDJ Death Cross.

Madrigal's 15-minute chart has recently triggered two bearish indicators: the MACD Death Cross and the KDJ Death Cross, both of which occurred on September 22, 2025 at 10:45. This suggests that the stock price may continue to decline, as the momentum of the stock price is shifting towards the downside and has the potential to further decrease.

Madrigal Pharmaceuticals' stock price recently triggered two significant bearish indicators: the MACD Death Cross and the KDJ Death Cross, both of which occurred on September 22, 2025, at 10:45. This suggests a potential decline in the stock price, as the momentum is shifting towards the downside. Investors and financial professionals should closely monitor these developments.

The MACD (Moving Average Convergence Divergence) Death Cross and KDJ (Kaufman Adaptive Moving Average) Death Cross are technical indicators used to predict changes in the direction of a stock's price. A Death Cross occurs when the MACD line crosses below the signal line, while the KDJ line crosses below the 20-period and 50-period moving averages. These signals often indicate a potential reversal in the stock's trend, suggesting a bearish outlook.

Madrigal Pharmaceuticals' stock price decline comes amid growing interest and investment in the metabolic dysfunction-associated steatohepatitis (MASH) space. Recently, Roche acquired 89bio for up to $3.5 billion, securing pegozafermin, a phase 3-stage candidate for the fatty liver disease Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug^[1]. The deal underscores the significant potential of MASH treatments, as the market continues to attract major pharmaceutical players.

Despite Madrigal's first-mover advantage in MASH, with the FDA approval of its medicine Rezdiffra in 2024, the market remains competitive. Analysts from Evercore ISI have noted that the MASH market offers room for multiple treatment options . The FDA is also considering using a noninvasive liver measurement as a surrogate endpoint for certain MASH patients, which could expedite drug development in this area.

Investors should be aware of the bearish indicators and the competitive landscape in the MASH market. While Madrigal's stock price decline may be a cause for concern, the company's position as a pioneer in MASH treatment should not be overlooked. As the market continues to evolve, investors should closely monitor Madrigal's performance and the broader trends in the MASH space.